Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
68382-0074-10 68382-0074 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec 5, 2017 In Use
68382-0244-16 68382-0244 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 21, 2021 In Use
60505-3802-08 60505-3802 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
68382-0074-06 68382-0074 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec 5, 2017 In Use
68382-0074-30 68382-0074 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec 5, 2017 Dec 3, 2019 In Use
68382-0244-05 68382-0244 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 21, 2021 In Use
00074-1044-01 00074-1044 Telisotuzumab Vedotin Telisotuzumab Vedotin 20.0 mg/mL Immunotherapy Drug Antibody Conjugate c-MET Intravenous May 14, 2025 In Use
83076-1025-03 83076-1025 Ensartinib ENSACOVE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, ROS1, MET Oral Apr 30, 2025 In Use
83076-1100-06 83076-1100 Ensartinib ENSACOVE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, ROS1, MET Oral Apr 30, 2025 In Use
68382-0074-01 68382-0074 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec 5, 2017 In Use
00074-1055-01 00074-1055 Telisotuzumab Vedotin Telisotuzumab Vedotin 100.0 mg/mL Immunotherapy Drug Antibody Conjugate c-MET Intravenous May 14, 2025 In Use
00338-0080-01 00338-0080 Doxorubicin Hydrochloride Liposome Doxorubicin Hydrochloride Liposome 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug 15, 2019 In Use
83654-0105-01 83654-0105 Penpulimab Penpulimab 100.0 mg/10mL Immunotherapy Monoclonal Antibody PD-1 Intravenous Apr 23, 2025 In Use
68382-0074-77 68382-0074 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec 5, 2017 In Use
51407-0986-90 51407-0986 Letrozole Tablets Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Feb 20, 2025 In Use
60505-3801-00 60505-3801 Nilotinib Nilotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
60505-3801-07 60505-3801 Nilotinib Nilotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
60505-3801-02 60505-3801 Nilotinib Nilotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
60505-3801-05 60505-3801 Nilotinib Nilotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
60505-3801-08 60505-3801 Nilotinib Nilotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
60505-3802-05 60505-3802 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
60505-3802-00 60505-3802 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
60505-3802-07 60505-3802 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
60505-3802-02 60505-3802 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
68382-0245-05 68382-0245 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 21, 2021 In Use

Found 11564 results — Export these results